The Efficacy and Safety of Nirmatrelvir/Ritonavir Against COVID-19 in Elderly Patients
Zheng Xiang,* Yueyuan Wang,* Yuchen Qu, Bo Lv, Junping Han, Delai Xu, Kai Fan, Cunjin Su, Zhu Shen Department of Pharmacy, The Second Affiliated Hospital of Soochow University, Suzhou, 215004, People’s Republic of China*These authors contributed equally to this workCorrespond...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2024-01-01
|
| Series: | International Journal of General Medicine |
| Subjects: | |
| Online Access: | https://www.dovepress.com/the-efficacy-and-safety-of-nirmatrelvirritonavir-against-covid-19-in-e-peer-reviewed-fulltext-article-IJGM |
| _version_ | 1797335770205257728 |
|---|---|
| author | Xiang Z Wang Y Qu Y Lv B Han J Xu D Fan K Su C Shen Z |
| author_facet | Xiang Z Wang Y Qu Y Lv B Han J Xu D Fan K Su C Shen Z |
| author_sort | Xiang Z |
| collection | DOAJ |
| description | Zheng Xiang,* Yueyuan Wang,* Yuchen Qu, Bo Lv, Junping Han, Delai Xu, Kai Fan, Cunjin Su, Zhu Shen Department of Pharmacy, The Second Affiliated Hospital of Soochow University, Suzhou, 215004, People’s Republic of China*These authors contributed equally to this workCorrespondence: Cunjin Su; Zhu Shen, Email sucjgh@vip.163.com; jsdxsz@163.comObjective: To assess the key factors influencing the effectiveness of nirmatrelvir/ritonavir in treating elderly patients with COVID-19.Methods: This study was conducted on patients aged ≥ 60 who were admitted to the Second Affiliated Hospital of Soochow University for COVID-19 infection and were treated with nirmatrelvir/ritonavir. Clinical information was collected from patients and steady-state blood concentrations of nirmatrelvir and ritonavir were measured. Factors associated with treatment effects were searched by univariate and multivariate analysis.Results: A total of 68 (51 males and 17 females) patients had a median age of 80 (73.0– 84.8) years were enrolled in this study. The blood concentration measurements (trough concentrations) of nirmatrelvir and ritonavir were 5.1 (2.6– 7.1) and 0.4 (0.2– 0.9) μg/mL, respectively. Adverse drug reaction was reported in 4 (5.9%) patients. Univariate analysis showed that age, clinical classification, APACHE II score, total bilirubin (TBil), aspartate transaminase (AST), lactate dehydrogenase (LDH), and total cholesterol (TC) were significantly associated with the effectiveness of treatment (P value < 0.05). Concentration of nirmatrelvir was also associated with treatment outcome (P value < 0.1). Based on the results of univariate analysis, the above factors were introduced into the multiple linear regression equation as independent variables, and the results showed that clinical classification was included in the regression equation model and was the most important factor affecting the treatment outcome. By receiver operating characteristic curve analysis, the area under curve of age + biochemical indicators + APACHE II score + clinical classification was 0.968 (95% CI = 0.919– 1.000; P < 0.0001). Among the 68 patients included in the study, 4 cases experienced adverse drug reactions.Conclusion: Age, clinical classification, APACHE II score, TBil, AST, LDH, and TC were significantly associated with the effectiveness of treatment in elderly patients with COVID-19.Keywords: nirmatrelvir/ritonavir, COVID-19, elderly patients, effectiveness |
| first_indexed | 2024-03-08T08:43:13Z |
| format | Article |
| id | doaj.art-3bbce70abf7b4de180a613fbd5018ab1 |
| institution | Directory Open Access Journal |
| issn | 1178-7074 |
| language | English |
| last_indexed | 2024-03-08T08:43:13Z |
| publishDate | 2024-01-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | International Journal of General Medicine |
| spelling | doaj.art-3bbce70abf7b4de180a613fbd5018ab12024-02-01T17:59:27ZengDove Medical PressInternational Journal of General Medicine1178-70742024-01-01Volume 1729730490042The Efficacy and Safety of Nirmatrelvir/Ritonavir Against COVID-19 in Elderly PatientsXiang ZWang YQu YLv BHan JXu DFan KSu CShen ZZheng Xiang,* Yueyuan Wang,* Yuchen Qu, Bo Lv, Junping Han, Delai Xu, Kai Fan, Cunjin Su, Zhu Shen Department of Pharmacy, The Second Affiliated Hospital of Soochow University, Suzhou, 215004, People’s Republic of China*These authors contributed equally to this workCorrespondence: Cunjin Su; Zhu Shen, Email sucjgh@vip.163.com; jsdxsz@163.comObjective: To assess the key factors influencing the effectiveness of nirmatrelvir/ritonavir in treating elderly patients with COVID-19.Methods: This study was conducted on patients aged ≥ 60 who were admitted to the Second Affiliated Hospital of Soochow University for COVID-19 infection and were treated with nirmatrelvir/ritonavir. Clinical information was collected from patients and steady-state blood concentrations of nirmatrelvir and ritonavir were measured. Factors associated with treatment effects were searched by univariate and multivariate analysis.Results: A total of 68 (51 males and 17 females) patients had a median age of 80 (73.0– 84.8) years were enrolled in this study. The blood concentration measurements (trough concentrations) of nirmatrelvir and ritonavir were 5.1 (2.6– 7.1) and 0.4 (0.2– 0.9) μg/mL, respectively. Adverse drug reaction was reported in 4 (5.9%) patients. Univariate analysis showed that age, clinical classification, APACHE II score, total bilirubin (TBil), aspartate transaminase (AST), lactate dehydrogenase (LDH), and total cholesterol (TC) were significantly associated with the effectiveness of treatment (P value < 0.05). Concentration of nirmatrelvir was also associated with treatment outcome (P value < 0.1). Based on the results of univariate analysis, the above factors were introduced into the multiple linear regression equation as independent variables, and the results showed that clinical classification was included in the regression equation model and was the most important factor affecting the treatment outcome. By receiver operating characteristic curve analysis, the area under curve of age + biochemical indicators + APACHE II score + clinical classification was 0.968 (95% CI = 0.919– 1.000; P < 0.0001). Among the 68 patients included in the study, 4 cases experienced adverse drug reactions.Conclusion: Age, clinical classification, APACHE II score, TBil, AST, LDH, and TC were significantly associated with the effectiveness of treatment in elderly patients with COVID-19.Keywords: nirmatrelvir/ritonavir, COVID-19, elderly patients, effectivenesshttps://www.dovepress.com/the-efficacy-and-safety-of-nirmatrelvirritonavir-against-covid-19-in-e-peer-reviewed-fulltext-article-IJGMnirmatrelvir/ritonavircovid-19elderly patientseffectiveness |
| spellingShingle | Xiang Z Wang Y Qu Y Lv B Han J Xu D Fan K Su C Shen Z The Efficacy and Safety of Nirmatrelvir/Ritonavir Against COVID-19 in Elderly Patients International Journal of General Medicine nirmatrelvir/ritonavir covid-19 elderly patients effectiveness |
| title | The Efficacy and Safety of Nirmatrelvir/Ritonavir Against COVID-19 in Elderly Patients |
| title_full | The Efficacy and Safety of Nirmatrelvir/Ritonavir Against COVID-19 in Elderly Patients |
| title_fullStr | The Efficacy and Safety of Nirmatrelvir/Ritonavir Against COVID-19 in Elderly Patients |
| title_full_unstemmed | The Efficacy and Safety of Nirmatrelvir/Ritonavir Against COVID-19 in Elderly Patients |
| title_short | The Efficacy and Safety of Nirmatrelvir/Ritonavir Against COVID-19 in Elderly Patients |
| title_sort | efficacy and safety of nirmatrelvir ritonavir against covid 19 in elderly patients |
| topic | nirmatrelvir/ritonavir covid-19 elderly patients effectiveness |
| url | https://www.dovepress.com/the-efficacy-and-safety-of-nirmatrelvirritonavir-against-covid-19-in-e-peer-reviewed-fulltext-article-IJGM |
| work_keys_str_mv | AT xiangz theefficacyandsafetyofnirmatrelvirritonaviragainstcovid19inelderlypatients AT wangy theefficacyandsafetyofnirmatrelvirritonaviragainstcovid19inelderlypatients AT quy theefficacyandsafetyofnirmatrelvirritonaviragainstcovid19inelderlypatients AT lvb theefficacyandsafetyofnirmatrelvirritonaviragainstcovid19inelderlypatients AT hanj theefficacyandsafetyofnirmatrelvirritonaviragainstcovid19inelderlypatients AT xud theefficacyandsafetyofnirmatrelvirritonaviragainstcovid19inelderlypatients AT fank theefficacyandsafetyofnirmatrelvirritonaviragainstcovid19inelderlypatients AT suc theefficacyandsafetyofnirmatrelvirritonaviragainstcovid19inelderlypatients AT shenz theefficacyandsafetyofnirmatrelvirritonaviragainstcovid19inelderlypatients AT xiangz efficacyandsafetyofnirmatrelvirritonaviragainstcovid19inelderlypatients AT wangy efficacyandsafetyofnirmatrelvirritonaviragainstcovid19inelderlypatients AT quy efficacyandsafetyofnirmatrelvirritonaviragainstcovid19inelderlypatients AT lvb efficacyandsafetyofnirmatrelvirritonaviragainstcovid19inelderlypatients AT hanj efficacyandsafetyofnirmatrelvirritonaviragainstcovid19inelderlypatients AT xud efficacyandsafetyofnirmatrelvirritonaviragainstcovid19inelderlypatients AT fank efficacyandsafetyofnirmatrelvirritonaviragainstcovid19inelderlypatients AT suc efficacyandsafetyofnirmatrelvirritonaviragainstcovid19inelderlypatients AT shenz efficacyandsafetyofnirmatrelvirritonaviragainstcovid19inelderlypatients |